Zentek Ltd. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Zentek Ltd.

ZEN.V 1.210

-0.8%

Oct 28 3:47 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: George69	10/24/2025 7:40:54 PM
	of 53889

Not Zentek related exactly but in my family: Janet PrinceJanet Prince • FollowingVerified • FollowingDriving Innovation in RNA Therapeutics \| Strategic Partnerships & Business Development \| Associate Director at D2RDriving Innovation in RNA Therapeutics \| Strategic Partnerships & Business Development \| Associate Director at D2R4d • Edited • 4 days ago • Edited • Visible to anyone on or off LinkedIn Exciting science straight from Maureen McKeague’s lab! Discover how her team is pushing the boundaries of RNA chemistry and AML therapeutic innovation. lnkd.in Olivia Kovecses Nathan Luedtke Francois Mercier Maureen McKeagueMaureen McKeague • 3rd+Verified • 3rd+Associate Professor \| Ph.D. in ChemistryAssociate Professor \| Ph.D. in Chemistry4d • Edited • 4 days ago • Edited • Visible to anyone on or off LinkedIn Follow Olivia Kovecses' new paper alert! RNA activation of CEBPA improves leukemia treatment, now published in Molecular Therapy Nucleic Acids Acute myeloid leukemia (AML) is a devastating blood cancer that often strikes suddenly and progresses fast, leaving few effective treatment options. This work is exciting because it shows that RNA can be selectively delivered into AML cells and used to switch on a transcription factor (C/EBPa) that’s normally considered “undruggable.” This opens the door to a new therapeutic strategy for one of the most aggressive forms of the disease (FLT3-mutated AML). The project brought together an amazing team spanning academia, industry, and clinical research minatx.com Nathan Luedtke and Francois Mercier. We gratefully acknowledge Canadian Cancer Society, CIHR, and Cole Foundation for scholarships and funding. I want to especially recognize our brilliant PhD student, Olivia, who was practically single-handedly responsible for this project. I’ve never seen such persistence, creativity, and dedication. She pushed through difficult experiments, learned animal work from scratch, and crossed Montreal almost daily to capture critical time points and measurements. Her determination and care made this study possible. The results are promising and open an entirely new area of research for this devastating disease. Paper: lnkd.in hashtag#RNAactivation hashtag#LeukemiaResearch hashtag#NucleicAcidTherapeutics hashtag#MiNATherapeutics hashtag#McGill Cristobal González-Losada, M.D., M.Sc. RNA activation of CEBPA improves leukemia

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next